In head and neck cancers with TP53 mutations, nanomedicines can be designed to deliver small molecules, gene-editing tools (such as CRISPR/Cas9), or RNA interference molecules (such as siRNA) to repair or replace the inactive TP53 function (Deneka et al., 2022). This evidence concerns the gene TP53 and head and neck cancer.